Last reviewed · How we verify
NCT01619917
The Role of Fractional Vascular Laser Therapy in the Management of Burn Scars
NA trial testing Fractional Vascular Laser in Burn Scar in 6 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | University of Manitoba |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 1 November 2012 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 July 2028 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Fractional Vascular Laser
Conditions studied
- Burn Scar — all drugs for Burn Scar →
Sponsor
University of Manitoba
Who can join
Adults 18 to 60, any sex, with Burn Scar. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
While the literature tends to support the use of laser therapy in the management of burn scars, there is a definite lack of appropriately powered, randomized controlled trials. Laser therapy can be quite expensive when compared to other treatment modalities for burn scars, and while promising, its true usefulness has yet to be conclusively demonstrated. For this reason, our assessing the effects of fractional vascular lasers on burn scars. It has been hypothesized that the fractional vascular lasers work on mature scars to decrease scar formation, and the fractional laser works on scar that is quiescent to promote remodelling. The retexturing/ resurfacing of the laser theoretically can decrease the visibility of the mesh pattern created by meshed split thickness skin graft). Objective: To determine the benefit of fractional vascular laser treatment in improving burn scar height, texture, vascularity and pliability in late burn scars.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advancements in Regenerative Strategies Through the Continuum of Burn Care.
Stone Ii R, Natesan S, Kowalczewski CJ, Mangum LH, et al · · 2018 · cited 73× · PMID 30038569 · DOI 10.3389/fphar.2018.00672
Verify or expand the search:
- PubMed search for NCT01619917
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Burn Scar
Currently open trials in the same condition.
- NCT06807021 — Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients · Phase 2, PHASE3 · recruiting
- NCT07213544 — Remimazolam vs Propofol in Laser Burn Cases · Phase 4 · recruiting
- NCT06801626 — Novel Strategies for Reducing Burn Scar Itch · Phase 3 · recruiting
- NCT06122090 — Treatment of Hypopigmented Scars With Bimatoprost · Phase 2 · recruiting
- NCT05423613 — Microneedling for Burn Hypertrophic Scars · NA · active not recruiting
Other University of Manitoba trials
Trials by the same sponsor.
- NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
- NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients · NA · not yet recruiting
- NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes · NA · enrolling by invitation
- NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias · NA · recruiting
- NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01619917 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
- Last refreshed: 4 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01619917.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing